Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Monopar Therapeutics (MNPR) Invested Capital (2016 - 2020)

Historic Invested Capital for Monopar Therapeutics (MNPR) over the last 5 years, with Q3 2020 value amounting to $17.6 million.

  • Monopar Therapeutics' Invested Capital rose 27966.61% to $17.6 million in Q3 2020 from the same period last year, while for Sep 2020 it was $17.6 million, marking a year-over-year increase of 27966.61%. This contributed to the annual value of $12.6 million for FY2019, which is 8252.56% up from last year.
  • As of Q3 2020, Monopar Therapeutics' Invested Capital stood at $17.6 million, which was up 27966.61% from $12.2 million recorded in Q2 2020.
  • In the past 5 years, Monopar Therapeutics' Invested Capital ranged from a high of $17.6 million in Q3 2020 and a low of $2.8 million during Q4 2016
  • Over the past 5 years, Monopar Therapeutics' median Invested Capital value was $8.1 million (recorded in 2018), while the average stood at $8.8 million.
  • As far as peak fluctuations go, Monopar Therapeutics' Invested Capital plummeted by 3895.16% in 2019, and later surged by 27966.61% in 2020.
  • Over the past 5 years, Monopar Therapeutics' Invested Capital (Quarter) stood at $2.8 million in 2016, then surged by 239.78% to $9.6 million in 2017, then decreased by 28.08% to $6.9 million in 2018, then skyrocketed by 82.53% to $12.6 million in 2019, then surged by 39.05% to $17.6 million in 2020.
  • Its last three reported values are $17.6 million in Q3 2020, $12.2 million for Q2 2020, and $12.4 million during Q1 2020.